Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas

Małgorzata Domagała-Haduch; Amanda Robek; Jakub Wnuk; Łukasz Michalecki; Iwona Gisterek

doi:10.5114/wo.2023.127013

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2023
vol. 27

Send email

Copy url:

abstract:

Original paper

Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas

Małgorzata Domagała-Haduch

¹

,

Amanda Robek

¹

,

Jakub Wnuk

¹

,

Łukasz Michalecki

¹

,

Iwona Gisterek

¹

Department of Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland

Contemp Oncol (Pozn) 2023; 27 (1): 10–13

DOI: https://doi.org/10.5114/wo.2023.127013

Online publish date: 2023/04/27

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Domagała-Haduch M, Robek A, Wnuk J, Michalecki Ł, Gisterek I. Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas. Contemporary Oncology/Współczesna Onkologia. 2023;27(1):10-13. doi:10.5114/wo.2023.127013.

APA

Domagała-Haduch, M., Robek, A., Wnuk, J., Michalecki, Ł.,  & Gisterek, I. (2023). Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas. Contemporary Oncology/Współczesna Onkologia, 27(1), 10-13. https://doi.org/10.5114/wo.2023.127013

Chicago

Domagała-Haduch, Małgorzata, Amanda Robek, Jakub Wnuk, Łukasz Michalecki,  and Iwona Gisterek. 2023. "Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas". Contemporary Oncology/Współczesna Onkologia 27 (1): 10-13. doi:10.5114/wo.2023.127013.

Harvard

Domagała-Haduch, M., Robek, A., Wnuk, J., Michalecki, Ł.,  and Gisterek, I. (2023). Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas. Contemporary Oncology/Współczesna Onkologia, 27(1), pp.10-13. https://doi.org/10.5114/wo.2023.127013

MLA

Domagała-Haduch, Małgorzata et al. "Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas." Contemporary Oncology/Współczesna Onkologia, vol. 27, no. 1, 2023, pp. 10-13. doi:10.5114/wo.2023.127013.

Vancouver

Domagała-Haduch M, Robek A, Wnuk J, Michalecki Ł, Gisterek I. Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas. Contemporary Oncology/Współczesna Onkologia. 2023;27(1):10-13. doi:10.5114/wo.2023.127013.

PlumX metrics:

Introduction:
Systemic treatment of pancreatic adenocarcinoma in the population of people over 65 years old is a challenge resulting from both the extremely unfavourable prognosis of this cancer and the particularly high sensitivity to the toxicity of chemotherapy in the elderly. This article presents the effectiveness and side effects of first-line chemotherapy according to the FOLFIRINOX regimen in patients over 65 years of age diagnosed with advanced pancreatic adenocarcinoma.

Material and methods:
The analysis was conducted in a group of 43 patients diagnosed with locally advanced inoperable pancreatic cancer or metastatic pancreatic cancer. Patients were treated between 2017 and 2021 in the Clinical Oncology Department, University Clinical Centre, Katowice, Poland.

Results:
In the study group, the median overall survival was 9.8 months; the median progression-free survival was 8.8 months. Treatment toxicity occurred in all patients. Adverse events of G3 and G4 severity (common terminology criteria for adverse events 5.0) occurred in 8% of patients. In 2 patients (5%), chemotherapy toxicity was the reason for discontinuation of systemic treatment.

Conclusions:
Triple-drug chemotherapy in a group of patients aged over 65 years with a diagnosis of advanced pancreatic cancer shows similar effectiveness to the general treated population, and with proper medical supervision the severity of side effects is at an acceptable level.

keywords:

Analysis of the efficacy and tolerability of FOLFIRINOX chemotherapy treatment in patients over 65 years of age with diagnosis of advanced adenocarcinoma of the pancreas

Małgorzata Domagała-Haduch 1 , Amanda Robek 1 , Jakub Wnuk 1 , Łukasz Michalecki 1 , Iwona Gisterek 1

pancreatic adenocarcinoma, adverse events, overall survival, progression-free survival, chemotherapy

Małgorzata Domagała-Haduch

¹

,

Amanda Robek

¹

,

Jakub Wnuk

¹

,

Łukasz Michalecki

¹

,

Iwona Gisterek

¹